Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1953 1
1961 1
1964 1
1965 3
1966 1
1967 3
1968 4
1970 4
1971 1
1972 2
1973 3
1974 3
1976 3
1977 6
1978 1
1979 9
1980 4
1981 2
1982 2
1983 7
1984 5
1985 7
1986 6
1987 7
1988 4
1989 7
1990 12
1991 8
1992 8
1993 16
1994 9
1995 10
1996 14
1997 12
1998 17
1999 15
2000 11
2001 7
2002 17
2003 14
2004 19
2005 27
2006 20
2007 43
2008 47
2009 44
2010 62
2011 71
2012 77
2013 95
2014 105
2015 106
2016 83
2017 115
2018 149
2019 139
2020 156
2021 161
2022 201
2023 189
2024 190
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,113 results

Results by year

Filters applied: . Clear all
Page 1
Synthetic lethality between TP53 and ENDOD1.
Tang Z, Zeng M, Wang X, Guo C, Yue P, Zhang X, Lou H, Chen J, Mu D, Kong D, Carr AM, Liu C. Tang Z, et al. Among authors: lou h. Nat Commun. 2022 May 23;13(1):2861. doi: 10.1038/s41467-022-30311-w. Nat Commun. 2022. PMID: 35606358 Free PMC article.
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM, Chadwick JA, Owen RP, White MJ, Kaplinsky J, Peneva I, Frangou A, Xie PF, Chang J, Roth A, Amess B, James SA, Rei M, Fuchs HS, McCann KJ, Omiyale AO, Jacobs BA, Lord SR, Norris-Bulpitt S, Dobbie ST, Griffiths L, Ramirez KA, Ricciardi T, Macri MJ, Ryan A, Venhaus RR, Van den Eynde BJ, Karydis I, Schuster-Böckler B, Middleton MR, Lu X; LUD2015-005 Project Team. Carroll TM, et al. Cancer Cell. 2023 Jul 10;41(7):1222-1241.e7. doi: 10.1016/j.ccell.2023.06.006. Cancer Cell. 2023. PMID: 37433281 Free article.
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, Liu D, Lou H, Bai L, Liu T, Li Y, Li Y, Fan Q, Feng M, Zhong H, Huang Y, Lou G, Wang J, Lin X, Chen Y, An R, Li C, Zhou Q, Huang X, Guo Z, Wang S, Li G, Fei J, Zhu L, Zhu H, Li X, Li F, Liao S, Min Q, Tang L, Shan F, Gong J, Gao Y, Zhou J, Lu Z, Li X, Li J, Ren H, Liu X, Yang H, Li W, Song W, Wang ZM, Li B, Xia M, Wu X, Ji J. Gao X, et al. Among authors: lou h. Lancet Oncol. 2023 Oct;24(10):1134-1146. doi: 10.1016/S1470-2045(23)00411-4. Lancet Oncol. 2023. PMID: 37797632 Clinical Trial.
2,113 results